FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) today announced the first patient implant of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System after being included on the Australian Register of Therapeutic Goods last month in Australia. The first implants were performed by Professor Ian Spark […]
Other News
Lexington Biosciences Announces Results of Annual General Meeting
VANCOUVER, British Columbia, July 02, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the results of its recent Annual General Meeting. The Company is pleased to announce that all matters before the Board were approved at the […]
Esperion to Host Analyst and Investor Day Event on July 10
ANN ARBOR, Mich., July 03, 2018 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced it will host an analyst and investor day in New […]
Morton Plant Hospital is First in Florida to Participate in Transcatheter Mitral Valve Replacement Pivotal Trial
CLEARWATER, Fla., July 2, 2018 /PRNewswire-USNewswire/ — On June 28, doctors at Morton Plant Hospital became the first in Florida to treat a patient in the APOLLO Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial. TMVR is a minimally invasive potential alternative to conventional open-heart mitral-valve surgery for patients with severe mitral valve regurgitation. Mitral valve regurgitation […]
Tiara and Reducer Featured at CSI Frankfurt 2018
VANCOUVER, July 2, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ (“Tiara”), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ (“Reducer”), a CE-Marked medical devices used for […]
Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement
VANCOUVER, July 2, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement on Form F-10 (the “Registration Statement”) with the U.S. Securities and […]
LivaNova to Host Conference Call for Second Quarter 2018 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second quarter 2018 results earlier […]
ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise® Ultrasound Denervation System For Treatment Of Hypertension
PALO ALTO, Calif., July 2, 2018 /PRNewswire/ — ReCor Medical announced today that the US Food & Drug Administration approved the Company’s new pivotal study of the Paradise Ultrasound Denervation System for the treatment of hypertension: RADIANCE-II. Building upon the recent positive results of the Company’s RADIANCE-HTN SOLO study, RADIANCE-II will be […]
CHMP issues positive opinion to expand Jardiance®, Synjardy® and Glyxambi® labels to include positive effects on cardiovascular and renal outcomes
INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update the labels of Jardiance® (empagliflozin), Synjardy® (empagliflozin and metformin) and Glyxambi® (empagliflozin and linagliptin) to include additional important […]
MIVI Neuroscience Announces First-In-Man Series of The DAISe Clot Management System
EDEN PRAIRIE, Minn., June 29, 2018 /PRNewswire/ — MIVI Neuroscience, Inc. announced today it has successfully achieved first-in-man usage of the DAISe Clot Management System for next generation treatment of ischemic stroke. The proprietary DAISe Clot Management System is uniquely designed to remove clot as well as filter / capture clot emboli that […]



